San Diego, CA – CanWell Pharma is pleased to announce its participation in the AACR Annual Meeting 2026, taking place from April 17–22, 2026, at the San Diego Convention Center.
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.
Conference Preview:
1.CanWell Pharma will present Phase 1 clinical trial data on the safety, tolerability, and preliminary efficacy of intratumoral injection of CAN2109 in the treatment of advanced solid tumors at the AACR meeting.
2.CanWell Pharma will present preclinical data on the superior antitumoral effects and favorable safety profile of CAN017, a first-in-class StarLinker™-based CLDN18.2/PD-L1 bispecific dual-payload ADC, at the AACR meeting.
3.CanWell Pharma will present preclinical data about a promising therapeutic for HER2-positive/mutant solid tumors, particularly in the post-ADC setting of CAN106 and its Phase 1 clinical trial study desgin of advanced solid tumors at the AACR meeting.